Cholera – Pipeline Review, H1 2019 Featuring Akthelia Pharmaceuticals, Beijing Minhai Biotechnology Co, and Napo Pharmaceuticals – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cholera
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Cholera – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Cholera (Infectious Disease), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Cholera (Infectious Disease) pipeline guide
also reviews of key players involved in therapeutic development for
Cholera and features dormant and discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1
respectively. Similarly, the Universities portfolio in Phase II, Phase
I, Preclinical and Discovery stages comprises 2, 1, 6 and 2 molecules,
respectively.

Cholera (Infectious Disease) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Cholera (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Cholera
  (Infectious Disease) by companies and universities/research institutes
  based on information derived from company and industry-specific
  sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Cholera
  (Infectious Disease) therapeutics and enlists all their major and
  minor projects.
• The pipeline guide evaluates Cholera (Infectious Disease) therapeutics
  based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Cholera (Infectious Disease)

Reasons to Buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Cholera (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Cholera (Infectious Disease) pipeline depth and focus of Indication
  therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Companies Mentioned

• Akthelia Pharmaceuticals Ltd.
• Beijing Minhai Biotechnology Co. Ltd.
• Napo Pharmaceuticals Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2oh2go

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Infectious
Diseases Drugs